ImmunoGen announced last week the addition of Howard Pien to the company’s board of directors. Pien was formerly the chairman and CEO of Chiron from 2003 to 2006, and led the company through its acquisition by Novartis last year. Prior to joining Chiron, Pien held positions at SmithKline Beecham and its successor, GlaxoSmithKline.
Sequenom announced this week that Steven Owings will assume the newly created position of VP of commercial development, prenatal diagnostics.
Owings joins Sequenom from Roche Diagnostics, where he held various managerial and sales positions for 20 years. From 1992 to 1997, Owings was the director of Roche’s PCR business unit. Prior to Roche, Owings worked for Digene.
Sequenom said it expects application of its non-invasive technology for fetal Rhesus D typing to first become available through a licensed clinical laboratory during the first half of this year.
Helicos BioSciences has added Gene Myers to its scientific advisory board. Myers is a professor at the Janelia Farm Research Campus of the Howard Hughes Medical Institute.
Myers was vice president of informatics research at Celera Genomics.
Metabolon has appointed three new members to its executive team, the company said last week:
Tim Germann was named vice president of sales. He previously headed the sales and marketing branch of US Genomics and was involved in product launches at Affymetrix.
Bruce Mcreedy was named new vice president of strategic development. He was an associate vice president of infectious diseases with LabCorp and was associate vice president at Triangle Pharmaceuticals and CEO at Fulcrum.
Dan Stevens has been named director of marketing. Stevens was formerly at Silicon Graphics and launched products at Procter and Gamble.
Xceed Molecular said last week it has appointed as president David Deems. He replaces Michael Cohen, who will become non-executive chairman of the board.
Deems was previously vice president of development and operations at Predicant Biosciences, where he had also been vice president of development and operations. He was also vice president of product development at Exact Sciences, CEO of Union Biometrica, and was an executive at BD Biosciences.
Safeguard Scientifics has added former Genomics Collaborative CEO Michael Pellini to its life sciences group as an executive in residence, the company said last week. In the position, Pellini will develop marketing opportunities, evaluate deals, and counsel the company on strategic development issues.
Most recently Pellini has served as COO of Lakewood Pathology Associates and was an entrepreneur in residence at BioAdvance.
Cepheid has renewed CEO John Bishop’s contract for four years to include a base salary of $450,000 and an annual bonus up to $225,000, the company said in a Securities and Exchange Commission filing last week.